Drug Dependence

🔍 Definition

Drug dependence (substance use disorder) is a chronic, relapsing brain disease characterized by compulsive drug seeking and use despite harmful consequences, driven by neurobiological changes in reward, stress, and inhibitory control circuits. Per the SAMHSA and American Psychiatric Association (APA), substance use disorders exist on a spectrum from mild to severe, formerly captured in DSM-IV as “abuse” and “dependence” — now unified under the DSM-5 framework as a single disorder with severity specifiers. For coding purposes, ICD-10-CM Chapter 5 (F10–F19) retains the use/abuse/dependence hierarchy per FY2027 ICD-10-CM Official Guidelines Section I.C.5.b.

The ICD-10-CM axis for this chapter organizes disorders by: (1) substance type (F10 alcohol through F19 other/multiple), (2) clinical severity within each substance (use, abuse, dependence, unspecified), and (3) associated complications (intoxication, withdrawal, mood disorder, psychotic disorder, etc.). Accurate code assignment requires the provider to explicitly document the specific substance, the level of use (use vs. abuse vs. dependence), and any active complications or comorbidities arising from the substance use.

📝 Coder Note

The ICD-10-CM hierarchy (use < abuse < dependence) is strictly hierarchical: if both abuse and dependence are documented for the same substance, code dependence only. If both use and abuse are documented, code abuse only. Never assign a lower-severity code when a higher-severity code is supported. See FY2027 Official Guidelines I.C.5.b.2.

🗂️ Alternative Terminology

Providers may use a wide variety of clinical, colloquial, and DSM-5/ICD terms. Coders and CDI specialists must recognize all of the following as potentially codeable diagnoses requiring clarification of severity and substance:

Formal / Clinical TermColloquial / Lay Terms & Synonyms
Substance use disorder (SUD)Drug problem, addiction, habit, substance abuse
Alcohol use disorder (AUD)Alcoholism, alcohol addiction, heavy drinking, problem drinking
Opioid use disorder (OUD)Opioid addiction, narcotic dependence, heroin addiction, opiate abuse
Cannabis use disorderMarijuana dependence, weed addiction, pot abuse
Cocaine use disorderCocaine addiction, crack dependence, cocaine abuse
Stimulant use disorderMeth addiction, amphetamine dependence, speed abuse, ADHD med misuse
Sedative/hypnotic/anxiolytic use disorderBenzo dependence, sleeping pill addiction, Xanax abuse, tranquilizer dependence
Tobacco use disorder / Nicotine dependenceSmoker, tobacco addict, cigarette dependence, nicotine addiction
Hallucinogen use disorderLSD abuse, PCP dependence, mushroom use disorder
Inhalant use disorderHuffing, glue sniffing, inhalant abuse
Polysubstance use disorderMultiple drug use, polydrug abuse, mixed substance dependence
Medication-Assisted Treatment (MAT)Suboxone treatment, methadone maintenance, Vivitrol therapy
Opioid withdrawal syndromeDope sickness, kicking the habit, detox
Neonatal abstinence syndrome (NAS)Baby withdrawal, neonatal drug withdrawal, P96.1
In remission (early/sustained)Clean, sober, recovery, not using, quit

🩺 Signs & Symptoms

Clinical manifestations vary by substance but share common themes of tolerance, withdrawal, and loss of control. The following align with DSM-5 criteria (APA DSM-5) and are organized by domain:

General Substance Use Disorder Criteria (DSM-5 — 2 or more = mild; 4–5 = moderate; 6+ = severe)

  • Taking larger amounts or over longer periods than intended
  • Persistent desire or unsuccessful efforts to cut down/control use
  • Great deal of time spent obtaining, using, or recovering from effects
  • Craving or strong urge to use
  • Failure to fulfill major role obligations (work, school, home)
  • Continued use despite social/interpersonal problems caused by substance
  • Important activities given up or reduced due to use
  • Recurrent use in physically hazardous situations
  • Continued use despite knowledge of persistent physical or psychological problems
  • Tolerance: need for markedly increased amounts; diminished effect with same amount
  • Withdrawal: characteristic syndrome; substance taken to relieve/avoid withdrawal

Substance-Specific Signs

  • Alcohol (F10): Tremors, diaphoresis, tachycardia, hypertension, seizures (delirium tremens), hepatomegaly, peripheral neuropathy, blackouts
  • Opioids (F11): Pinpoint pupils, respiratory depression, sedation, nausea/vomiting; withdrawal: rhinorrhea, lacrimation, piloerection, diarrhea, tachycardia, restlessness, COWS score >8
  • Cannabis (F12): Conjunctival injection, increased appetite, dry mouth, impaired memory, amotivational syndrome
  • Sedatives (F13): Ataxia, slurred speech, cognitive impairment; withdrawal: anxiety, insomnia, tremor, seizures — potentially life-threatening
  • Cocaine/Stimulants (F14/F15): Tachycardia, hypertension, dilated pupils, paranoia, nasal septum perforation (cocaine), hyperthermia; crash: fatigue, depression, hypersomnia
  • Nicotine/Tobacco (F17): Cravings, irritability, anxiety, difficulty concentrating, increased appetite on cessation; clinically silent long-term toxicity (COPD, CAD, lung cancer)
  • Hallucinogens (F16): Perceptual distortions, flashbacks (HPPD), dissociation, autonomic arousal
  • Inhalants (F18): Sudden sniffing death, perioral rash, chemical odor, encephalopathy

🧭 Differential Diagnosis

Distinguishing substance use disorders from related and comorbid conditions is critical for accurate ICD-10-CM coding. Many neuropsychiatric symptoms may be substance-induced or represent independent comorbidities — documentation must distinguish between the two per FY2027 Official Guidelines Section I.C.5.b.

Differential ConditionKey Distinguishing FeaturesRelevant Code(s)
Substance-induced mood disorderMood symptoms arise during/after substance use; resolve with abstinence (weeks). Code as complication of SUD (e.g., F11.24)F1x.14, F1x.24, F1x.94
Independent major depressive disorderMood disorder predates SUD or persists >4 weeks post-cessation; requires separate codingF32.x + F1x.xx
Substance-induced psychotic disorderPsychosis during intoxication/withdrawal; resolves with abstinence. Code as complication (e.g., F11.25x)F1x.15x, F1x.25x, F1x.95x
Schizophrenia spectrum disordersPsychosis persists independent of substance use; onset often earlier; code separatelyF20.x + F1x.xx
Benzodiazepine therapeutic dependencePrescribed use producing physiological dependence ≠ SUD; if intentional misuse or SUD criteria met, then F13.2x appliesF13.2x vs. T42.4x5A (adverse effect)
Opioid-induced constipation / side effectAdverse effect of properly administered opioid; no SUD criteria met; code T40.xx5A (adverse effect)T40.2x5A + K59.09
Chronic pain on prescribed opioids (no SUD)Physiological dependence on prescribed opioids without SUD = Z79.891 (long-term use), NOT F11.2xZ79.891
Alcohol-related dementia vs. Alzheimer’sWernicke-Korsakoff, alcohol-induced persisting amnestic disorder = F10.26; verify provider documentationF10.26, F10.27, G31.2
Nicotine dependence vs. tobacco useIf dependence not documented → Z72.0 (tobacco use). If dependence documented → F17.2xx. Critical for CDI queryF17.2xx vs. Z72.0
Neonatal abstinence syndrome vs. other neonatal conditionsNAS (P96.1) requires maternal substance use during pregnancy; differentiate from metabolic neonatal conditionsP96.1, O99.32x
⚠️ Common Pitfall

Do not code F11.2x (opioid dependence) for a patient receiving prescribed opioids for chronic pain who meets no SUD criteria. Instead, use Z79.891 (long-term [current] use of opiate analgesic) when supported. This distinction is critical for compliance and accurate risk adjustment. Similarly, F13.2x (sedative/hypnotic/anxiolytic dependence) should only be assigned when provider documentation supports a sedative, hypnotic, or anxiolytic use disorder/dependence — not merely because physiological tolerance has developed to a prescribed benzodiazepine.

📋 Clinical Indicators

The following indicators — when present in the medical record — suggest a codeable substance use disorder, a higher severity level, or a complication requiring additional codes. CDI specialists should review these triggers and query when documentation is absent or ambiguous.

Clinical IndicatorDocumentation Element NeededPotential Code Impact
Active substance use noted in history or nursing notesProvider attestation of use, abuse, or dependence; specific substanceF1x.1x, F1x.2x — possible HCC 135–139 opportunity depending on substance, severity, and complication; verify current CMS-HCC V28 mapping
CAGE, AUDIT, or DAST screening positiveProvider clinical diagnosis; screen alone insufficient to codeQuery for SUD diagnosis; Z13.89 for screening only
Urine/serum drug screen positiveProvider confirmation of diagnosis; correlation with clinical findingsDo not code from lab alone; query provider
Patient on Suboxone / buprenorphine-naloxoneIndication: OUD MAT vs. chronic pain; if OUD → F11.2x; if chronic pain → Z79.891F11.20–F11.29 vs. Z79.891
Patient on methadone maintenance programMethadone for OUD MAT vs. chronic pain analgesic; document OUD if MATF11.20 + Z79.891 (if also on opioid for pain)
Patient on naltrexone (Vivitrol)Indication: alcohol use disorder or OUD; document whichF10.2x or F11.2x
CIWA protocol initiatedAlcohol withdrawal — specify severity; code F10.239 or F10.231/F10.232F10.23x — MS-DRG impact
COWS score >8 documentedOpioid withdrawal; provider to specify dependence with withdrawalF11.23 — HCC 137 under CMS-HCC V28
Active smoker in any settingIs dependence documented? Duration? Type of tobacco product? Complication on cessation?F17.210 vs. Z72.0 — critical CDI opportunity
Pregnancy + substance useType of substance, trimester, delivery vs. antepartum; NAS for newbornO99.32x + F1x.xx; P96.1 for neonate
Polysubstance useCode each substance separately when identified; use F19 only when substance truly unknown or cannot be separatedMultiple F codes vs. F19.xx
“In remission” documentationProvider documentation of remission and SUD severity; mild SUD in remission maps to the appropriate abuse-in-remission code, while moderate/severe SUD in remission maps to the appropriate dependence-in-remission codeHCC impact varies by code and payment model; verify current risk-adjustment mapping
OD/poisoning admissionSpecify substance, intent (accidental/intentional/assault), and encounter type (initial, subsequent, sequela)T40.xx1A (accidental initial) + F1x.xx
💬 CDI Query Trigger

When a patient is documented as a “smoker” or has smoking listed as a social history item without a specific diagnosis, query the provider: “Does this patient have nicotine/tobacco dependence (F17.2xx), or should tobacco use be coded as Z72.0? If dependence is present, what is the product type (cigarettes, chewing tobacco, other) and are there any associated complications or withdrawal symptoms?” Tobacco dependence (F17.21x) carries quality-measure, cessation-counseling, and comorbidity-documentation implications, but nicotine dependence does not generally map to a payment HCC under CMS-HCC V28.

🦴 Anatomy & Pathophysiology

Substance use disorders involve disruption of the brain’s mesolimbic dopamine reward pathway — colloquially called the “reward circuit” — involving the ventral tegmental area (VTA), nucleus accumbens, prefrontal cortex, and amygdala. Per NIDA (National Institute on Drug Abuse), all addictive substances trigger dopamine surges 2–10× greater than natural rewards, reinforcing drug-seeking behavior through neuroplastic changes.

Key Neurobiological Mechanisms by Substance Class

  • Alcohol (F10): Enhances GABA-A receptor activity (inhibitory) and inhibits NMDA glutamate receptors (excitatory). Chronic use leads to compensatory upregulation of NMDA and downregulation of GABA, causing CNS hyperexcitability on withdrawal — the basis of alcohol withdrawal seizures and delirium tremens (F10.231, F10.232).
  • Opioids (F11): Bind mu, kappa, and delta opioid receptors; suppress pain and activate reward via dopamine disinhibition. Chronic use causes receptor downregulation and desensitization → tolerance. Abrupt cessation unmasks noradrenergic hyperactivity (locus coeruleus) → withdrawal syndrome (F11.23).
  • Cannabis (F12): THC binds CB1 cannabinoid receptors in prefrontal cortex, hippocampus, and cerebellum, disrupting memory consolidation and executive function. Long-term use associated with amotivational syndrome and cannabis use disorder in ~9% of users per NIDA cannabis research.
  • Sedatives/Benzodiazepines (F13): Similar to alcohol — GABA potentiation. Withdrawal shares life-threatening features (seizures, delirium). Cross-tolerance with alcohol. Physiological dependence can develop within 4–6 weeks of daily therapeutic use.
  • Cocaine/Stimulants (F14/F15): Block dopamine, norepinephrine, and serotonin reuptake transporters → massive monoamine surge. Methamphetamine also causes direct monoamine release. Chronic use depletes dopamine stores, causing anhedonia and depression in withdrawal (“crash”).
  • Nicotine (F17): Binds nicotinic acetylcholine receptors (nAChR), particularly α4β2 in VTA → dopamine release. Neuroadaptation to nicotine is rapid; cessation triggers irritability, anxiety, difficulty concentrating, and intense craving (F17.213 withdrawal).
  • Hallucinogens (F16): Classic psychedelics (LSD, psilocybin) act as 5-HT2A receptor agonists. Phencyclidine (PCP) is an NMDA receptor antagonist. Dissociative anesthetic at high doses.
  • Inhalants (F18): Volatile hydrocarbons enhance GABA and inhibit NMDA activity; direct CNS, cardiac, hepatic, and renal toxicity. Sudden sniffing death via cardiac dysrhythmia.

💊 Medication Impact / Treatment

Pharmacological treatment of substance use disorders is evidence-based and FDA-approved for several substance classes. Medication-Assisted Treatment (MAT) for opioid use disorder represents the gold standard per SAMHSA MAT guidelines and ASAM Clinical Practice Guidelines.

FDA-Approved Pharmacotherapy by Substance

  • Opioid Use Disorder (F11.2x):
    • Buprenorphine (Subutex)/Buprenorphine-Naloxone (Suboxone): Partial mu-opioid agonist; first-line MAT/MOUD. HCPCS J0570–J0575 (buprenorphine formulations), J0592 (buprenorphine hydrochloride injection). Code OUD (F11.2x) when documented; use G2086/G2087/G2088 for Medicare office-based SUD treatment bundles when requirements are met.
    • Methadone (opioid agonist): Full mu-agonist; dispensed at licensed OTPs (opioid treatment programs). HCPCS J3490 (unclassified). Both F11.20 (dependence, uncomplicated) + Z79.891 may apply when methadone serves dual purpose.
    • Naltrexone (Vivitrol): Opioid antagonist; blocks effects. Injectable monthly formulation. HCPCS J2315. Appropriate for sustained remission maintenance.
    • Naloxone (Narcan): Emergency opioid reversal — NOT maintenance treatment; for acute poisoning (T40.xx1A).
  • Alcohol Use Disorder (F10.2x):
    • Naltrexone (oral/injectable): Reduces craving. HCPCS J2315 (Vivitrol IM).
    • Acamprosate (Campral): Reduces withdrawal-related dysphoria; restores GABA/glutamate balance. Oral only.
    • Disulfiram (Antabuse): Aversion therapy — causes acetaldehyde accumulation with alcohol ingestion → nausea, flushing, tachycardia.
    • Benzodiazepines (CIWA protocol): Management of acute alcohol withdrawal (F10.23x) — diazepam, lorazepam, chlordiazepoxide.
  • Nicotine/Tobacco Use Disorder (F17.2xx):
    • Nicotine Replacement Therapy (NRT): Patches, gum, lozenge, inhaler, nasal spray — reduce withdrawal severity.
    • Varenicline (Chantix/Champix): Partial α4β2 nAChR agonist; most effective single agent per AHRQ Clinical Practice Guideline for Treating Tobacco Use.
    • Bupropion (Zyban): NDRI; reduces craving and withdrawal. Can combine with NRT.
  • Stimulant/Cocaine Use Disorder: No FDA-approved pharmacotherapy; contingency management and CBT are mainstay per NIDA treatment principles.
📝 Coder Note

Z79.891 (long-term current use of opiate analgesic) applies when a patient has a documented legitimate therapeutic use of opiates. It does NOT indicate dependence/SUD. When the indication for buprenorphine or methadone is OUD MAT, assign the appropriate F11.2x code. When methadone is used for chronic pain in a patient with no active SUD, use Z79.891 + chronic pain code. Dual use (both pain management and MAT for OUD) is possible and both codes may apply per clinical context.

Preview ends here. The full guide continues with FY2027 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines

The following summarizes key coding guidance from FY2027 ICD-10-CM Official Guidelines, Section I.C.5 (Mental, Behavioral and Neurodevelopmental Disorders) for substance use disorders:

1. Use/Abuse/Dependence Hierarchy (I.C.5.b.2)

  • If both use and abuse are documented for the same substance → code abuse only
  • If both abuse and dependence are documented for the same substance → code dependence only
  • If both use and dependence are documented → code dependence only
  • Assign the code that reflects the highest documented level of severity

2. Psychoactive Substance Use, Unspecified (I.C.5.b.3 — “Use” codes)

Unspecified psychoactive substance use codes (F10.9-, F11.9-, F12.9-, F13.9-, F14.9-, F15.9-, F16.9-, F18.9-, F19.9-) should be assigned only from provider documentation and only when they meet the definition of a reportable diagnosis. These codes are used only when the psychoactive substance use is associated with a substance-related disorder or medical condition and that relationship is documented by the provider.

3. In Remission Coding

  • Mild substance use disorders in early or sustained remission are classified to the appropriate substance abuse in remission code (for example, F1x.11 when available for that substance). Provider documentation must support that the condition is in remission.
  • Moderate or severe substance use disorders in early or sustained remission are classified to the appropriate substance dependence in remission code (for example, F1x.21 when available for that substance). ICD-10-CM uses the same remission code for early and sustained remission; duration remains clinical documentation detail rather than a separate ICD-10-CM character.
  • Provider documentation must explicitly state “in remission” — do not infer from MAT alone.

4. Coding Concurrent Substance Use Disorders

When a patient has multiple substance use disorders, assign separate codes for each substance. Use F19 (other psychoactive substance) only when the substance is truly unknown or multiple substances cannot be individually identified.

5. Psychoactive Substance-Induced Disorders

When a substance use disorder causes a mental or behavioral complication (psychosis, mood disorder, anxiety, sleep disorder, sexual dysfunction, etc.), code the SUD with the appropriate complication 5th/6th character rather than using a separate F-code for the mental disorder. Example: F11.24 (opioid dependence with opioid-induced mood disorder) rather than F11.20 + F32.9.

6. Poisoning vs. Adverse Effect vs. Underdosing (T40.xx)

  • Poisoning intent character: accidental/unintentional (1), intentional self-harm (2), assault (3), undetermined (4); for T36–T50 poisoning codes, intent is built into the 5th or 6th character, and unknown or unspecified intent defaults to accidental intent.
  • Adverse effect (5th character = 5): Correct drug, correct dose, properly administered; adverse reaction occurs
  • Underdosing (5th character = 6): Taking less than prescribed; use Z91.14 (noncompliance with medication) as additional code
  • Initial encounter: A; subsequent: D; sequela: S

7. Pregnancy and Substance Use

In pregnant patients, assign O99.32x (drug use complicating pregnancy/childbirth/puerperium) as the primary obstetric code, followed by the substance-specific F code. For newborns affected by maternal substance use: P96.1 (neonatal withdrawal symptoms from maternal use of drugs of addiction).

8. Tobacco Dependence — Critical Documentation Note

When a provider documents tobacco/nicotine dependence → assign F17.2xx (requires 5th character for product type and 6th character for complication). When only tobacco use is documented (no dependence) → assign Z72.0. The distinction carries significant clinical, risk-adjustment, and quality measure implications. Every smoking documentation encounter should trigger a CDI review per CDC tobacco control guidelines.

🔢 ICD-10-CM Code Set (Tabular)

All codes below are valid for FY2027 (effective October 1, 2026). Source: CMS/NCHS FY2027 ICD-10-CM tabular list.

F10 — Alcohol-Related Disorders

CodeDescriptionNotes
F10.10Alcohol abuse, uncomplicatedUse when abuse documented, no complications
F10.11Alcohol abuse, in remissionEarly or sustained remission; document duration
F10.120Alcohol abuse with intoxication, uncomplicatedAcute intoxication with abuse level SUD
F10.129Alcohol abuse with intoxication, unspecified
F10.130Alcohol abuse with withdrawal, uncomplicatedUse CIWA documentation to support
F10.131Alcohol abuse with withdrawal deliriumDTs in abuse context
F10.132Alcohol abuse with withdrawal with perceptual disturbanceHallucinations
F10.14Alcohol abuse with alcohol-induced mood disorderDepression/mania induced by alcohol in abuse context
F10.150Alcohol abuse with alcohol-induced psychotic disorder with delusions
F10.151Alcohol abuse with alcohol-induced psychotic disorder with hallucinations
F10.19Alcohol abuse with unspecified alcohol-induced disorder
F10.20Alcohol dependence, uncomplicatedHCC 139 under CMS-HCC V28 — verify current payment-year mapping
F10.21Alcohol dependence, in remissionEarly or sustained; important for continuity coding
F10.220Alcohol dependence with intoxication, uncomplicated
F10.229Alcohol dependence with intoxication, unspecified
F10.230Alcohol dependence with withdrawal, uncomplicatedCIWA-Ar used for management
F10.231Alcohol dependence with withdrawal deliriumDelirium tremens (DTs); MS-DRG impact
F10.232Alcohol dependence with withdrawal with perceptual disturbanceWithdrawal hallucinations
F10.239Alcohol dependence with withdrawal, unspecifiedUse only when complication unspecified
F10.24Alcohol dependence with alcohol-induced mood disorderDepressive/bipolar features — secondary to alcohol
F10.250Alcohol dependence with alcohol-induced psychotic disorder with delusions
F10.251Alcohol dependence with alcohol-induced psychotic disorder with hallucinations
F10.26Alcohol dependence with alcohol-induced persisting amnestic disorderKorsakoff syndrome — memory impairment
F10.27Alcohol dependence with alcohol-induced persisting dementiaAlcohol-induced persisting dementia in alcohol dependence; do not add a separate dementia code unless an independent dementia condition is documented
F10.280Alcohol dependence with alcohol-induced anxiety disorder
F10.281Alcohol dependence with alcohol-induced sexual dysfunction
F10.282Alcohol dependence with alcohol-induced sleep disorder
F10.288Alcohol dependence with other alcohol-induced disorder
F10.29Alcohol dependence with unspecified alcohol-induced disorder
F10.90Alcohol use, unspecified, uncomplicatedUse/unspecified — lowest RAF; query for upgrade
F10.920Alcohol use, unspecified with intoxication, uncomplicated
F10.99Alcohol use, unspecified with unspecified alcohol-induced disorder

F11 — Opioid-Related Disorders

CodeDescriptionNotes
F11.10Opioid abuse, uncomplicatedAbuse level — not meeting dependence criteria
F11.11Opioid abuse, in remissionEarly or sustained remission
F11.120Opioid abuse with intoxication, uncomplicated
F11.121Opioid abuse with intoxication delirium
F11.122Opioid abuse with intoxication with perceptual disturbance
F11.14Opioid abuse with opioid-induced mood disorder
F11.150Opioid abuse with opioid-induced psychotic disorder with delusions
F11.151Opioid abuse with opioid-induced psychotic disorder with hallucinations
F11.19Opioid abuse with unspecified opioid-induced disorder
F11.20Opioid dependence, uncomplicatedHCC 137 under CMS-HCC V28 — OUD without current complications; verify current payment-year mapping
F11.21Opioid dependence, in remissionEarly (3–12 mo) or sustained (>12 mo) — per DSM-5; lower/non-HCC
F11.220Opioid dependence with intoxication, uncomplicated
F11.221Opioid dependence with intoxication delirium
F11.222Opioid dependence with intoxication with perceptual disturbance
F11.229Opioid dependence with intoxication, unspecified
F11.23Opioid dependence with withdrawalHCC 137 under CMS-HCC V28; COWS score >8 may support withdrawal; MOUD/MAT initiation encounter
F11.24Opioid dependence with opioid-induced mood disorderSecondary depression/mania — do not separately code F32.x
F11.250Opioid dependence with opioid-induced psychotic disorder with delusions
F11.251Opioid dependence with opioid-induced psychotic disorder with hallucinations
F11.259Opioid dependence with opioid-induced psychotic disorder, unspecified
F11.281Opioid dependence with opioid-induced sexual dysfunction
F11.282Opioid dependence with opioid-induced sleep disorder
F11.288Opioid dependence with other opioid-induced disorder
F11.29Opioid dependence with unspecified opioid-induced disorderUse when complication unspecified
F11.90Opioid use, unspecified, uncomplicatedLowest code — query for upgrade to abuse/dependence
F11.920Opioid use, unspecified with intoxication, uncomplicated
F11.93Opioid use, unspecified with withdrawal

F12–F19 — Other Substance-Related Disorders (Summary)

CodeDescriptionNotes
F12.10Cannabis abuse, uncomplicatedMarijuana abuse
F12.11Cannabis abuse, in remission
F12.20Cannabis dependence, uncomplicatedHCC 137; cannabis use disorder severe
F12.21Cannabis dependence, in remission
F12.23Cannabis dependence with withdrawalValid in FY2027; document provider-diagnosed withdrawal syndrome carefully
F12.25xCannabis dependence with psychotic disorderF12.250 (delusions), F12.251 (hallucinations)
F12.90Cannabis use, unspecified, uncomplicated
F13.10Sedative/hypnotic/anxiolytic abuse, uncomplicatedBenzo abuse, sleeping pill abuse
F13.20Sedative/hypnotic/anxiolytic dependence, uncomplicatedHCC 137
F13.21Sedative dependence, in remission
F13.230Sedative dependence with withdrawal, uncomplicatedLife-threatening — similar to alcohol withdrawal
F13.231Sedative dependence with withdrawal deliriumBenzodiazepine withdrawal delirium
F13.232Sedative dependence with withdrawal with perceptual disturbance
F13.90Sedative use, unspecified, uncomplicated
F14.10Cocaine abuse, uncomplicated
F14.20Cocaine dependence, uncomplicatedHCC 137
F14.21Cocaine dependence, in remission
F14.23Cocaine dependence with withdrawal
F14.90Cocaine use, unspecified, uncomplicated
F15.10Other stimulant abuse, uncomplicatedAmphetamine, methamphetamine, caffeine
F15.20Other stimulant dependence, uncomplicatedHCC 137
F15.21Other stimulant dependence, in remission
F15.23Other stimulant dependence with withdrawal
F15.90Other stimulant use, unspecified, uncomplicated
F16.10Hallucinogen abuse, uncomplicatedLSD, PCP, psilocybin abuse
F16.20Hallucinogen dependence, uncomplicated
F16.21Hallucinogen dependence, in remission
F16.90Hallucinogen use, unspecified, uncomplicated
F17.200Nicotine dependence, unspecified, uncomplicatedCRITICAL: use when product type unspecified; triggers quality measures
F17.201Nicotine dependence, unspecified, in remissionProduct type unspecified; use only when provider documents nicotine dependence in remission
F17.208Nicotine dependence, unspecified, with other nicotine-induced disorders
F17.209Nicotine dependence, unspecified, with unspecified nicotine-induced disorders
F17.210Nicotine dependence, cigarettes, uncomplicatedMost common; assign when cigarette dependence documented
F17.211Nicotine dependence, cigarettes, in remissionCigarette dependence in remission; code tobacco-related conditions such as COPD, CAD, or lung cancer separately when documented
F17.213Nicotine dependence, cigarettes, with withdrawalCessation counseling encounter — irritability, craving, weight gain
F17.218Nicotine dependence, cigarettes, with other nicotine-induced disorders
F17.219Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders
F17.220Nicotine dependence, chewing tobacco, uncomplicatedSmokeless tobacco dependence
F17.221Nicotine dependence, chewing tobacco, in remissionSmokeless tobacco dependence in remission
F17.223Nicotine dependence, chewing tobacco, with withdrawal
F17.290Nicotine dependence, other tobacco product, uncomplicatedE-cigarettes, vaping, cigars, pipe — “other” products
F17.291Nicotine dependence, other tobacco product, in remissionOther tobacco product dependence in remission
F17.293Nicotine dependence, other tobacco product, with withdrawal
F18.10Inhalant abuse, uncomplicatedHuffing, glue sniffing
F18.20Inhalant dependence, uncomplicatedHCC 137
F18.21Inhalant dependence, in remission
F18.90Inhalant use, unspecified, uncomplicated
F19.10Other psychoactive substance abuse, uncomplicatedMultiple/unknown substances — abuse level
F19.20Other psychoactive substance dependence, uncomplicatedHCC 137; polysubstance dependence when substances undifferentiated
F19.21Other psychoactive substance dependence, in remission
F19.23Other psychoactive substance dependence with withdrawal
F19.90Other psychoactive substance use, unspecified, uncomplicated

Associated / Supplementary Codes

CodeDescriptionContext / Use
Z79.891Long-term (current) use of opiate analgesicPrescribed opioids for pain — NOT dependence; also for MAT when dual purpose; do NOT assign with F11.2x dependence unless dual use applies
Z72.0Tobacco useTobacco use without documented dependence; query to upgrade to F17.2xx
Z91.14Patient’s other noncompliance with medication regimenUnderdosing of prescribed substances; use with T40.xx6A (underdosing)
T40.0X1APoisoning by opium, accidental (unintentional), initial encounterHeroin overdose — accidental; add 7th character for encounter type
T40.1X1APoisoning by heroin, accidental, initial encounterHeroin OD — more specific than T40.0X1A when heroin identified
T40.2X1APoisoning by other opioids, accidental, initial encounterPrescription opioid OD (oxycodone, hydrocodone, morphine)
T40.3X1APoisoning by methadone, accidental, initial encounterMethadone OD — distinguish from therapeutic use
T40.411APoisoning by other synthetic narcotics, accidental, initial encounterFentanyl OD — critical given epidemic; fentanyl analogs included
T40.5X1APoisoning by cocaine, accidental, initial encounterCocaine OD
T50.905APoisoning by other and unspecified drugs/medicinal/biological substances, adverse effect, initial encounterUnspecified medicinal substance adverse effect
O99.320Drug use complicating pregnancy, unspecified trimesterSubstance use in pregnancy — add F code
O99.321Drug use complicating pregnancy, first trimester
O99.322Drug use complicating pregnancy, second trimester
O99.323Drug use complicating pregnancy, third trimester
O99.324Drug use complicating childbirth
O99.325Drug use complicating the puerperium
P96.1Neonatal withdrawal symptoms from maternal use of drugs of addictionNAS — neonatal abstinence syndrome; assign on newborn record
Z13.89Encounter for screening for other disorderWhen SBIRT screening performed but no diagnosis established
🛡️ Audit Alert

Fentanyl overdose coding (T40.411A) is under intense scrutiny in 2026 given the ongoing opioid/fentanyl epidemic. Ensure: (1) the 7th character correctly reflects encounter type (A=initial, D=subsequent, S=sequela); (2) the intent character is accurate (1=accidental, 2=intentional self-harm, 3=assault, 4=undetermined); (3) F11.2x or F11.90 is assigned in addition to capture the underlying OUD; (4) naloxone administration is documented; and (5) MAT initiation is captured for eligible patients per SAMHSA OUD treatment guidelines.

🔎 Indexing

When indexing substance use disorders in the Alphabetic Index of the FY2027 ICD-10-CM, use these primary index terms and lead terms:

Index Term / Lead TermSubterm PathCode Result
Dependencedrug → opioid → with withdrawalF11.23
Dependencedrug → alcohol → with delirium tremensF10.231
Dependencenicotine → cigarettesF17.210
Abusedrug → cannabisF12.10
Use (of)cannabis → harmful NECF12.90
Disordersubstance use → opioid → mildF11.10 (abuse per ICD hierarchy)
Disordersubstance use → opioid → severeF11.20
Withdrawalstate → alcoholF10.239
Withdrawalstate → opioidF11.23
Poisoningheroin → accidentalT40.1X1A
Poisoningfentanyl → accidentalT40.411A
Syndromeneonatal abstinenceP96.1
Statuslong-term (current) use → opiate analgesicZ79.891
Tobacco use(no subterm — use as lead term)Z72.0
Nicotine dependence→ cigarettes → with withdrawalF17.213

Note on Tabular Sequencing: For poisoning encounters, T40.xx codes are principal/first-listed, followed by the substance use disorder (F code) and any manifestation codes (e.g., respiratory failure J96.0x). For SUD management/detox encounters, the F code is principal. For MAT encounters, the OUD code (F11.20) is principal with Z79.891 as additional when applicable.

🏥 CPT

CPT codes for substance use disorder services are sourced from the AMA CPT 2027 Standard Edition. Behavioral health and substance use services may require appropriate modifier use, POS designation, and payer-specific coverage policies.

CPT CodeDescriptionGlobalNotes
99406Smoking and tobacco cessation counseling visit, intermediate, 3–10 minXXXPhysician/QHP; preventive service; typically covered by payers as preventive
99407Smoking and tobacco cessation counseling visit, intensive, >10 minXXXMost comprehensive tobacco cessation code; document time in chart
99408Alcohol and/or substance (other than tobacco) abuse structured screening, brief intervention (SBIRT), 15–30 minXXXAUDIT, DAST, or validated screen + brief counseling; document tool used
99409Alcohol and/or substance (other than tobacco) abuse structured screening, brief intervention (SBIRT), >30 minXXXExtended brief intervention; document time
96127Brief emotional/behavioral assessment with scoring and documentationXXXPHQ-2, CAGE, AUDIT-C screening tools — can bill per instrument
90832Psychotherapy, 30 minXXXIndividual therapy for SUD — requires medical necessity; time-based
90834Psychotherapy, 45 minXXXCBT, motivational interviewing for substance use
90837Psychotherapy, 60 minXXXIntensive individual therapy for SUD comorbidities
90853Group psychotherapy (other than of a multiple-family group)XXX12-step facilitation, group CBT for SUD
90870Electroconvulsive therapy (including necessary monitoring)XXXRarely indicated; for refractory depression comorbid with SUD
99213–99215Office or other outpatient E/M, established patient (moderate-high complexity)XXXMAT management visits (OUD on buprenorphine); MDM includes prescription drug management
H0001Alcohol and/or drug assessment—Behavioral health — state-plan/Medicaid; initial assessment
H0004Behavioral health counseling and therapy, per 15 min—Time-based individual counseling for SUD
H0005Alcohol and/or drug services; group counseling by a clinician—Group therapy — SUD programs
H0014Ambulatory detoxification; per diem—Outpatient detox programs
H0015Alcohol and/or drug services; intensive outpatient (per diem)—IOP level of care — 9+ hours/week
H0016Medical/somatic (medical intervention in drug/alcohol treatment), per diem—Medically monitored/managed detox
H0018Alcohol and/or drug services; short-term residential (non-hospital residential), per diem—Residential treatment — short-term
H0019Alcohol and/or drug services; long-term residential, per diem—Long-term residential treatment program
H0020Alcohol and/or drug services; methadone administration and/or service—OTP services for methadone maintenance
H0022Alcohol and/or drug intervention service (planned facilitation)—Family intervention facilitation
H0050Alcohol and/or drug services; brief intervention, per 15 min—SBIRT — Medicaid behavioral health
📝 Coder Note

For office-based SUD treatment under Medicare, use G2086/G2087/G2088 (see HCPCS section) when the bundled-service requirements are met rather than 99213–99215 alone. Medicare covers monthly office-based SUD treatment bundles that may include overall management, care coordination, individual and group psychotherapy, and substance use counseling. Medicaid programs may use H-codes (H0001–H0050) instead. Always verify payer-specific coverage policies before billing substance use services, as coverage varies significantly by payer and state per CMS SUD coverage guidelines.

🧾 HCPCS

HCPCS Level II codes for substance use disorder treatment and medication-assisted treatment are sourced from the CMS HCPCS 2026 code set. These codes are essential for Medicare/Medicaid billing of OUD-specific services and drug formulations.

HCPCS CodeDescriptionTypical Use
G2086Office-based treatment for a substance use disorder, including development of the treatment plan, care coordination, individual therapy and group therapy and counseling; at least 70 min in the first calendar monthFirst month of office-based SUD treatment; bundled service — do not bill separately for components
G2087Office-based treatment for a substance use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 min in subsequent calendar months of treatmentMonthly maintenance of office-based SUD treatment (months 2+)
G2088Office-based treatment for a substance use disorder, including care coordination, individual therapy and group therapy and counseling; each additional 30 min beyond the first 120 minAdditional time beyond G2086/G2087 threshold
G0396Alcohol and/or substance (other than tobacco) abuse structured assessment (e.g., AUDIT, DAST) and brief intervention 15 to 30 minutesSBIRT in Medicare settings; AUDIT/DAST tool required
G0397Alcohol and/or substance (other than tobacco) abuse structured assessment (e.g., AUDIT, DAST) and intervention, greater than 30 minutesExtended SBIRT; document time
J0570Buprenorphine implant, 74.2 mgProbuphine implant for OUD — subdermal
J0571Buprenorphine, oral, 1 mgOral buprenorphine (Subutex); for induction/maintenance
J0572Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphineSuboxone lower doses
J0573Buprenorphine/naloxone, oral, greater than 3 mg but less than or equal to 6 mg buprenorphineSuboxone mid-range dosing
J0574Buprenorphine/naloxone, oral, greater than 6 mg but less than or equal to 10 mg buprenorphineSuboxone — standard maintenance dose range
J0575Buprenorphine/naloxone, oral, greater than 10 mg buprenorphineHigher-dose Suboxone maintenance
J0592Buprenorphine hydrochloride, 0.3 mg injectionInjectable buprenorphine — inpatient/ED administration
J2315Injection, naltrexone, extended release, 1 mgVivitrol (380 mg/dose = 380 units); monthly IM injection for OUD or AUD
J3490Unclassified drugsMethadone (when no specific J-code); oral methadone for OTP — requires prior authorization from payers
H0014Ambulatory detoxification, per diemOutpatient detox services for any substance
H0020Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program)Methadone maintenance — OTP programs; per diem billing
H0033Oral medication administration, direct observationDOT (directly observed therapy) for methadone/buprenorphine in OTP
H0047Alcohol and/or other drug abuse services; not otherwise specifiedNOS behavioral health SUD services — use when specific code unavailable

📚 AHA Coding Clinic

The following AHA Coding Clinic references provide authoritative guidance on challenging substance use disorder coding scenarios. Coders should consult the full Coding Clinic text for complete guidance:

ReferenceTopicKey Guidance
ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.21.c.3; ICD-10-CM Alphabetic Index FY 2027, Disorder, opioid useOpioid use disorder and buprenorphine maintenanceCategory Z79 is not for use of medications for detoxification or maintenance programs to prevent withdrawal symptoms (e.g., methadone maintenance for opiate dependence); assign the appropriate code for the drug use, abuse, or dependence instead. Opioid use disorder, moderate or severe, is coded F11.20 (mild is F11.10). Z79.891, Long term (current) use of opiate analgesic, is for long-term opiate therapy, not for a maintenance program for opioid dependence.
ICD-10-CM Tabular List FY 2027, code Z79.891; ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.21.c.3Methadone maintenance vs. methadone for painZ79.891, Long term (current) use of opiate analgesic, includes long term (current) use of methadone for pain management and has an Excludes2 note for use of methadone for treatment of heroin addiction (F11.2-). Methadone maintenance for opiate dependence is coded to the dependence code (F11.2-), not to Z79.
AHA Coding Clinic, 4Q 2018, “Newborn Affected by Noxious Substances Transmitted via Placenta or Breast Milk”; ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.15.l.3Neonatal abstinence syndrome and maternal codingNewborn record: P96.1, Neonatal withdrawal symptoms from maternal use of drugs of addiction (includes neonatal abstinence syndrome), is sequenced first, with a code identifying the substance; for example, withdrawal due to the mother’s use of opiates is coded P96.1 and P04.14. Maternal record: assign a code from subcategory O99.32-, Drug use complicating pregnancy, childbirth, and the puerperium, with secondary code(s) from categories F11-F16 and F18-F19 to identify manifestations of the drug use.
ICD-10-CM Alphabetic Index FY 2027, Delirium, tremens; ICD-10-CM Tabular List FY 2027, code F05 Excludes2 note; AHA Coding Clinic, 4Q 2020, “Withdrawal Syndrome in Substance Use and Abuse”Alcohol withdrawal delirium (delirium tremens)Delirium tremens (alcohol-induced) indexes to F10.231, Alcohol dependence with withdrawal delirium. F05 has an Excludes2 note for delirium tremens (alcohol-induced or unspecified) (F10.231, F10.921), and F10.231 is a combination code that captures the withdrawal delirium (Section I.B.9). Since October 1, 2020, withdrawal codes also exist for alcohol abuse (F10.13-) and alcohol use (F10.93-), so withdrawal delirium in a patient documented with abuse or use, rather than dependence, is coded F10.131 or F10.931.
AHA Coding Clinic, 4Q 2018, “Cannabis Dependence and Cannabis Use with Withdrawal”; AHA Coding Clinic, 4Q 2020, “Withdrawal Syndrome in Substance Use and Abuse”Cannabis withdrawal (F12.23)Code F12.23, Cannabis dependence with withdrawal, was created to identify cannabis withdrawal syndrome in a patient with cannabis dependence, and F12.93, Cannabis use, unspecified with withdrawal, for physiological withdrawal in a person using cannabis regularly in contexts not defined as dependence. Code F12.13, Cannabis abuse with withdrawal, was added effective October 1, 2020.
AHA Coding Clinic, 4Q 2017, “Substance Related Disorders, in Remission”; ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.5.b.1In remission coding: early vs. sustainedICD-10-CM does not differentiate early from sustained remission in the code. Substance use disorder, mild, in early or sustained remission is coded to abuse in remission (for example, F11.11), and moderate or severe in early or sustained remission is coded to dependence in remission (for example, F11.21). Selection of the “in remission” codes requires the provider’s clinical judgment and documentation.
ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.19.e.5.(b); AHA Coding Clinic, 4Q 2020, “Synthetic Narcotics”Fentanyl overdose: T40.41- with F11.2-Fentanyl has its own subcategory (T40.41-), effective October 1, 2020 (FY 2021), as announced in Coding Clinic 4Q 2020. For a poisoning, sequence the T40.41- code first (for example, T40.411A for accidental poisoning, initial encounter; use accidental intent when intent is not documented). When opioid dependence is also documented, assign it as an additional code from F11.2-.
AHA Coding Clinic, 4Q 2013, “Smoker (Tobacco Use versus Dependence)”; ICD-10-CM Tabular List FY 2027, code Z72.0 Excludes1 noteNicotine dependence vs. tobacco use: documentation clarityA provider diagnosis of “smoker” is coded to nicotine dependence, F17.200; the Alphabetic Index directs Smoker, see Dependence, drug, nicotine. Assign F17.21- (for example, F17.210) when dependence on cigarettes is documented. Z72.0, Tobacco use, has an Excludes1 note for nicotine dependence (F17.2-), so it is not reported with an F17.2- code.
⚠️ Common Pitfall

Do not separately code substance-induced mental disorders when they are captured as 5th/6th character complications of the SUD code. For example, F11.24 already captures opioid-induced mood disorder — do not additionally assign F32.9 (major depressive disorder, single episode, unspecified). However, if an independent (non-substance-induced) psychiatric condition is documented as a comorbidity, it should be coded separately in addition to the SUD code, per FY2027 Official Guidelines I.C.5.b.

💰 HCC / Risk Adjustment

Substance use HCCs in V28 are HCCs 135–139 and depend on the substance, the severity, and any complication. Mappings below follow the 2024 CMS-HCC model (commonly called V28), which CMS uses at 100 percent for non-PACE Medicare Advantage risk scores and continued for CY 2027, and the CMS 2027 Initial ICD-10-CM Mappings. Coefficients vary by enrollee segment and payer, so this guide does not quote RAF weights; check the current CMS model software. Hierarchies are applied by CMS after coding: code every documented, supported condition.

ICD-10-CM Code(s)DescriptionV28 HCCCoding / Documentation Notes
F11.-, F13.-, F14.-, F15.-, F16.-, F18.-, F19.- with psychotic disorder (for example, F11.150, F14.259)Drug use with psychotic complicationsHCC 135 — Drug Use with Psychotic ComplicationsDrops HCCs 136–139
F10.- with psychotic disorder, withdrawal delirium, or withdrawal with perceptual disturbance (for example, F10.150, F10.231, F10.232)Alcohol use with psychotic complicationsHCC 136 — Alcohol Use with Psychotic ComplicationsDrops HCCs 137–139
F11.20, F11.21, F12.20, F13.20, F14.20, F15.20, F16.20, F18.20, F19.20 (and other non-psychotic complications)Drug dependence (moderate/severe use disorder), including in remissionHCC 137 — Drug Use Disorder, Moderate/Severe, or Drug Use with Non-Psychotic ComplicationsCannabis dependence (F12.2-) is included
F11.10, F13.10, F14.10, F15.10, F16.10, F18.10, F19.10 (and .11)Drug abuse (mild use disorder), uncomplicated or in remission, except cannabisHCC 138 — Drug Use Disorder, Mild, Uncomplicated, Except CannabisF12.10 (cannabis abuse) maps to no HCC
F10.20, F10.21, F10.230, F10.239, and F10.1-/F10.2- with specified non-psychotic complicationsAlcohol dependence; alcohol use with specified non-psychotic complicationsHCC 139 — Alcohol Use Disorder, Moderate/Severe, or Alcohol Use with Specified Non-Psychotic Complications—
F10.10, F10.11, F12.10, F12.90, F17.-Alcohol abuse, uncomplicated or in remission; cannabis abuse or use; nicotine dependenceNo V28 payment HCC—

When use, abuse, and dependence of the same substance are documented, assign only one code following the hierarchy in Guideline I.C.5.b.2. A disease interaction applies when a substance use HCC (135–139) occurs with a psychiatric HCC (151–155). V24 HCCs 54, 55, and 56 no longer apply.

🛡️ Audit Alert — Remission

“In remission” codes require the provider’s clinical judgment (Guideline I.C.5.b.1). Medication-assisted treatment on the medication list does not by itself establish dependence or remission.

Sources: CMS 2027 Initial ICD-10-CM Mappings (2024 CMS-HCC model, V28); CMS CY 2024 Rate Announcement, Attachment VI (hierarchies, interactions); FY 2027 ICD-10-CM Tabular List, Index, and Official Guidelines. Verified November 3, 2026.

✍️ CDI Query Templates

All queries below comply with AHIMA CDI Query Guidelines and ACDIS Practice Standards: non-leading, multiple-choice format, clinically based, and tied to documented clinical indicators.

Clinical Scenario / TriggerQuery Wording (Non-Leading, Multiple Choice)
Chart notes “smoker” but no dependence diagnosis“The patient is documented as a current smoker/tobacco user. Can you clarify the appropriate clinical diagnosis? Options: (A) Nicotine dependence, cigarettes, uncomplicated (F17.210); (B) Nicotine dependence, cigarettes, in remission (F17.211); (C) Nicotine dependence, cigarettes, with withdrawal (F17.213); (D) Nicotine dependence, cigarettes, with other nicotine-induced disorders (F17.218) or unspecified nicotine-induced disorders (F17.219); (E) Tobacco use (Z72.0); (F) Clinically undetermined. Please also specify product type if other than cigarettes.”
Patient on Suboxone/buprenorphine — OUD vs. pain management“The patient is currently prescribed buprenorphine/naloxone (Suboxone). Can you clarify the clinical indication? Options: (A) Medication-Assisted Treatment for opioid use disorder (OUD) — dependence (F11.20 or F11.21); (B) Pain management — long-term opiate analgesic use (Z79.891); (C) Both — dual indication for OUD MAT and pain management; (D) Clinically undetermined.”
Opioid use documented but severity unclear“The medical record documents opioid use. Based on the clinical presentation, history, and DSM-5 criteria, can you confirm the appropriate diagnostic level? Options: (A) Opioid dependence (F11.20); (B) Opioid dependence, in remission (F11.21) — if in remission, please indicate early [3–12 months] or sustained [>12 months]; (C) Opioid abuse (F11.10); (D) Opioid use, unspecified (F11.90); (E) Clinically undetermined.”
Alcohol withdrawal protocol (CIWA) initiated“A CIWA protocol was initiated for this patient. Can you confirm the appropriate clinical diagnosis? Options: (A) Alcohol dependence with withdrawal, uncomplicated (F10.230); (B) Alcohol dependence with withdrawal delirium [delirium tremens] (F10.231); (C) Alcohol dependence with withdrawal with perceptual disturbance [hallucinations] (F10.232); (D) Alcohol abuse with withdrawal (F10.130); (E) Clinically undetermined.”
Fentanyl/opioid overdose — intent unclear“The patient presented with a suspected opioid (fentanyl) overdose. Can you confirm: (1) Was this accidental/unintentional, intentional self-harm, or undetermined intent? (2) Is an underlying opioid use disorder present? Options for SUD: (A) Opioid dependence (F11.20); (B) Opioid abuse (F11.10); (C) Opioid use, unspecified (F11.90); (D) No opioid use disorder — adverse effect of therapeutic use; (E) Clinically undetermined.”
Multiple substances documented — polysubstance vs. individual codes“The patient has use/abuse/dependence documented for multiple substances. Can you clarify: (1) Is each substance individually identified (e.g., opioids AND cocaine AND cannabis)? If so, please confirm the severity level for each. (2) Or should this be coded as polysubstance/multiple drug use (F19.xx)? Identifying each substance separately when possible ensures the most accurate coding per ICD-10-CM guidelines.”
Patient states “clean” — in remission vs. active SUD“The patient reports being ‘clean/sober’ from [substance]. To confirm the appropriate diagnosis: (A) Mild substance use disorder in remission — appropriate F1x.11 abuse-in-remission code when available; (B) Moderate/severe substance use disorder in remission — appropriate F1x.21 dependence-in-remission code when available; (C) Active substance use disorder with current reduced/controlled use; (D) Resolved/history only — no active SUD diagnosis warranted; (E) Clinically undetermined. Please document remission status and severity if clinically known.”
Pregnant patient with documented drug use“This pregnant patient has documented [substance] use. Can you confirm: (1) The specific substance; (2) Severity level (use, abuse, or dependence); (3) Whether this complicates the pregnancy (O99.32x)? The newborn record should be queried regarding neonatal abstinence syndrome (P96.1) if applicable.”

🧑‍⚕️ Treatments (Clinical)

Treatment of substance use disorders is multimodal, integrating pharmacotherapy, behavioral interventions, and social support, guided by ASAM Clinical Practice Guidelines, SAMHSA treatment protocols, and the NIDA Principles of Drug Addiction Treatment.

ASAM Levels of Care

  • Level 0.5: Early Intervention (SBIRT) — outpatient, <9 hours/week. CPT 99406–99409, G0396–G0397.
  • Level 1: Outpatient Services — scheduled sessions, <9 hours/week. Individual/group therapy, MAT prescribing.
  • Level 2.1: Intensive Outpatient (IOP) — 9–19 hours/week structured programming. H0015 per diem.
  • Level 2.5: Partial Hospitalization — 20+ hours/week medical monitoring. H0035 per diem.
  • Level 3.1–3.7: Residential — medically monitored to managed inpatient detox/residential. H0018–H0019. MS-DRGs 895–897 (alcohol, drug abuse without/with CC/MCC).
  • Level 4: Medically Managed Intensive Inpatient — hospital-based; MS-DRG 895 (drug/alcohol dependence, left AMA), 896 (with CC), 897 (without CC/MCC).

Behavioral Therapies

  • Cognitive Behavioral Therapy (CBT): Identifies and modifies maladaptive thought patterns; evidence-based for cocaine, cannabis, alcohol. CPT 90834–90837.
  • Motivational Interviewing (MI): Patient-centered counseling to resolve ambivalence about change; used in brief intervention (SBIRT) and ongoing treatment.
  • Contingency Management (CM): Voucher/prize-based reinforcement of abstinence; most evidence for stimulant use disorders (no FDA-approved pharmacotherapy).
  • 12-Step Facilitation (TSF): Structured engagement with AA/NA; group therapy. CPT 90853.
  • Dialectical Behavior Therapy (DBT): Useful for borderline personality + SUD comorbidity.

Inpatient Detoxification Protocols

  • Alcohol detox: CIWA-Ar scale-guided benzodiazepine taper; seizure precautions; IV thiamine 100 mg for Wernicke prevention; electrolyte management. MS-DRG 895–897.
  • Opioid detox: Buprenorphine induction (COWS-guided, score ≥8–12 for induction), clonidine for autonomic symptoms, anti-diarrheal/anti-emetic supportive care. COWS protocol per SAMHSA buprenorphine guidance.
  • Benzodiazepine detox: Long-acting benzo taper (diazepam/chlordiazepoxide) with slow reduction schedule; seizure monitoring — potentially life-threatening withdrawal identical to alcohol.
  • Stimulant detox: Supportive only; manage depression, sleep disturbance, suicidal ideation during crash phase.

🎓 Patient Education / Summary

When providing patient education on substance use disorders, use accessible, non-stigmatizing language consistent with SAMHSA anti-stigma guidelines. Key patient education points:

  • Substance use disorder is a medical condition, not a moral failing. Like diabetes or hypertension, it involves changes in brain chemistry that require treatment and ongoing management.
  • Recovery is possible. Evidence-based treatments — including medications and therapy — are effective. Most people who engage in treatment improve significantly over time.
  • Medication-Assisted Treatment (MAT) is not “just substituting one drug for another.” Buprenorphine, methadone, and naltrexone are FDA-approved, evidence-based treatments that reduce overdose deaths, cravings, and illicit drug use. Per SAMHSA MAT data, MAT reduces opioid use, criminal activity, and risk of HIV/Hepatitis C transmission.
  • Tobacco dependence is among the most common and most treatable substance use disorders. Combination therapy (NRT + varenicline or bupropion) with behavioral support maximizes success rates. The AHRQ Treating Tobacco Use Guideline recommends offering cessation treatment at every clinical encounter.
  • Naloxone (Narcan) is a life-saving medication that reverses opioid overdose. Patients with OUD and their household contacts should receive a naloxone prescription at every opportunity. Many states allow pharmacist dispensing without a prescription.
  • If you or someone you know needs help: SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7, 365-day-a-year); SAMHSA Treatment Locator; findtreatment.gov.
  • For coders and CDI specialists: Accurate documentation and coding of substance use disorders supports continuity of care, appropriate risk adjustment, and access to specialized treatment benefits for patients. Complete documentation — specifying substance, severity, complications, and treatment — serves the patient first and foremost.


About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2027 ICD-10-CM (effective October 1, 2026). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: October 2026 · Next scheduled review: October 2027 (FY2028 update)

Ready to turn this knowledge into a credential?

These Clinical Documentation Guides are a free companion to CCO’s paid training programs. Browse our full CCO Course, Blitz & Practice Exam Catalog — every core course, review blitz, practice exam, textbook, and free resource in one place — and find the perfect next step for your coding career.

CCO Hero

Know someone starting a medical coding career?

Share your personal CCO link. Your friend saves 20% on their first course or practice exam of $100 or more, and you earn 5% cash on their first enrollment over $100.

Become a CCO Hero
Photo of author

CCO Certified Professionals

The CCO Certified Professionals team brings together experienced, credentialed medical coders, CDI specialists, and clinical documentation experts with decades of combined expertise in inpatient, outpatient, and risk-adjustment coding. Every Clinical Documentation Guide is built and reviewed by certified instructors who teach, code, and audit in the field every day. Content is verified against current ICD-10-CM, AHA Coding Clinic, and CMS guidance.

Leave a Comment

Clinical Doc Guides

⚊